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Open access under the ElsHuman cysticercosis caused by Taenia crassiceps is rare however it is considered of zoonotic risk. The treat-
ment of the infected patients was successful when using albendazole or praziquantel. The active forms of
albendazole inhibit the glucose uptake and the active forms of praziquantel alter glycogen levels and nutri-
ents absorption. The aim of this study was to analyze the production of organic acids that indicate the oxi-
dation of fatty acids and the use of alternative energy sources from T. crassiceps cysticerci removed from the
peritoneal cavity of mice treated with low dosages of albendazole (5.75 and 11.5 mg/kg) or praziquantel
(3.83 and 7.67 mg/kg). The beta-hydroxibutyrate production was higher by the larval stage cysticerci in
all treated groups and the propionate production was higher in ﬁnal stage cysticerci treated with
11.5 mg/kg of albendazole when compared to the control group. The larval stages of cysticerci from the
groups treated with 5.75 mg/kg of albendazole and 3.83 mg/kg of praziquantel produced more urea than
the initial and ﬁnal stages which indicate amino acids breakdown. We conclude that it was possible to
detect the fatty acid oxidation and amino acids breakdownwhich indicate theuse of alternative energypro-
duction sources as the used dosages only cause a partial blockage of the glucose uptake and leads to met-
abolic alterations in the cysticerci. Themetabolic behavior observed after host treatmentwasdifferent from
former descriptions of the in vitro one which indicates great host-parasite interaction.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
In some regions of theworldTaeniidaeparasites still remainpub-
lic health issues (Hoberg et al., 2000). Taenia crassiceps has wild ca-
nids as deﬁnitive host and may infect domestic ones, and rodents
as intermediate hosts such as rats and marmots (Saeed et al.,
2006; Bagrade et al., 2009; Stien et al., 2010; Willms and Zurabian,
2010). Human cysticercosis caused by T. crassiceps is rare however
it constitutes a zoonotic risk especially to immunocompromised
individuals accordingly to reports from France, Germany and
England (Wünschmann et al., 2003). Cysticerci were detected in
skeletonmuscles, central nervous system, intra-ocular and subcuta-
neous regions. The treatment of these patients was successful when
albendazole and praziquantel were used (Shea et al., 1973; Arocker-
Mettinger et al., 1992; Klinker et al., 1992; Chermette et al., 1995;
François et al., 1998; Maillard et al., 1998; Heldwein et al., 2006).
Albendazole is a drug from the benzimidazole group. Its active
forms are effective when the host is treated and after in vitro expo-
sure of adult forms, eggs and larvae of nematodes and cestodes35 esq com 1a, Av. s/n Setor
il. Fax: +55 62 3209 6363.
aud).
evier OA license.(Horton, 2000; Marques et al., 2002). In those parasites the mode
of action of this drug consists of the inhibition of the polymeriza-
tion of beta-tubulin leading to inadequate levels of energy which
are inconsistent to the helminth survival resulting in paralysis
and death (Horton, 2000; Palomares et al., 2006). Praziquantel is
considered the drug of choice in treatment campaigns due to its
low cost and its pharmacologic properties against several parasites
including Schistosoma mansoni and Taenia solium (Cioli et al., 1995;
Cioli and Pica-Mattoccia, 2003; Doenhoff et al., 2009; Cederberg
et al., 2012). Its active metabolites lead to muscle contractions, teg-
ument injuries, alter the muscle glycogen levels and inﬂuence the
nutrient absorption (Cioli et al., 1995; Cioli and Pica-Mattoccia,
2003; Jeziorski and Greenberg, 2006; Palomares et al., 2006).
The energetic metabolism from helminths in adult and larval
forms differ from the host metabolism showing a great variety of
nutrient catabolism pathways and the use of carbohydrates, fatty
acids and proteins as energy production sources (Kita et al.,
1997). In contrast with free living organisms parasites are nutri-
tionally dependent from their hosts. The variety of habitats during
its life cycle induces complex nutritional and biochemical adapta-
tions to insure the parasite survival (Köhler and Voigt, 1988).
There are in vitro and in vivo reports on the diffusion
mechanisms and mode of action of antihelminthic drugs such as
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2008, 2009), as well as reports of ultra structural injuries
(Palomares et al., 2004, 2006; Palomares-Alonso et al., 2007) and
structural ones in T. crassiceps cysticerci (Venkatesan, 1998; Cioli
et al., 1995; Cioli and Pica-Mattoccia, 2003; Horton, 2000) related
to exposure to these drugs. There are also in vitro reports that eval-
uate the excretion/secretion of organic acids related to metabolic
alterations of glycolytic pathways and the tricarboxylic acid cycle
after the exposure to these drugs (Vinaud et al., 2007, 2008) and
the detection of energy production from alternative energy sources
such as fatty acid oxidation (Vinaud et al., 2009).
However there is not a report of the use of these alternative en-
ergy sources by T. crassiceps cysticerci after the host treatment.
Therefore the aim of this study was to analyze the production of
organic acids that indicate the oxidation of fatty acids such as ace-
tate, acetoacetate, beta-hydroxybutirate and propionate, and eval-
uate the use of alternative energy sources such as amino acids
breakdown through urea and creatinine dosages in T. crassiceps
cysticerci after the host treatment with low dosages of albendazole
or praziquantel.2. Materials and methods
2.1. Maintenance of the T. crassiceps biological cycle
The biological cycle of T. crassiceps (ORF strain) has been main-
tained in the vivarium of the Tropical Pathology and Public Health
Institute from the Federal University of Goias (IPTSP/UFG) since
2002. Ten initial phase cysticerci were inoculated in the intraperi-
toneal cavity of 8–12 week old female BALB/c mice where they
multiplied by budding. Approximately 90 days after inoculation
the animals were euthanized and necropsied. The cysticerci were
removed from the intraperitoneal cavity, 10 initial phase speci-
mens were selected (Vinaud et al., 2008) and inoculated in other
non-infected mice for cycle continuation (Espíndola et al., 2002;
Vaz et al., 1997).
The ethical principles for animal experimentation professed by
the Brazilian society of laboratory animal sciences (Sociedade Bra-
sileira de Ciência em Animais de Laboratório/SBCAL) were followed
and this study was authorized by the Committee for Ethical Re-
search of the Federal University of Goias (CoEp/UFG) (registration
number 008/09).
The mice received daily care, acidiﬁed water and standard
rations.2.2. Mice infection and treatment
The BALB/c female mice were intraperitoneally inoculated with
10 initial phase T. crassiceps cysticerci (Vinaud et al., 2008), using
1 mL syringes. Thirty days after infection they were gavage treated
with low single doses of praziquantel (Merck) and albendazole
(Vitapan), 24 h after treatment they were euthanized for better
observation of the biochemical effects of the drugs on the
cysticerci.
The infected mice were divided into four groups, namely, group
A: consisting of ﬁve infected mice treated with a single dose of
5.75 mg/kg of albendazole; group B: consisting of ﬁve infected
mice treated with a single dose of 11.5 mg/kg of albendazole;
group C: consisting of ﬁve infected mice treated with a single dose
of 3.83 mg/kg of praziquantel; group D: consisting of ﬁve infected
mice treated with a single dose of 7.67 mg/kg of praziquantel. A
control group was formed consisting of ﬁve infected mice that
did not receive treatment.
All the experiment was performed in quintuplicate. The
doses applied were determined according to the manufacturer’srecommendation and the recommended to cysticercosis treatment
(Matthaiou et al., 2008) and then reduced to a level lower than nec-
essary to eliminate the parasite, as the purpose of the study was to
access the adaptability of the parasite to the drugs.2.3. Cysticerci biochemical analysis
The cysticerci removed from the mice were classiﬁed macro-
scopically according to their evolutionary phase as initial, larval
and ﬁnal (Vinaud et al., 2007). The specimens were ﬁxed in liquid
nitrogen, homogenized with 12% perchloric acid as described by
Vinaud et al. (2007), and then the organic acids were extracted
for chromatographic analysis as described by Bezerra et al.
(1999) and Vinaud et al. (2007, 2008).
The organic acids were identiﬁed through high performance li-
quid chromatography (HPLC) according to the previously deter-
mined retention time and calibration. The organic acids analyzed
were the ones which indicate the fatty acids metabolism such as
acetate, acetoacetate, beta-hydroxybutirate and propionate (Bezer-
ra et al., 1999; Vinaud et al., 2007, 2008).
After the samples were homogenized with 12% percloric acid
they were centrifuged at 500 g/10 min and from the supernatant
the urea and creatinine dosages were performed by dose response
spectrophotometry using a KoneLab 60i apparatus, according to
the commercial kit protocol, enzymatic method, Wiener lab.2.4. Statistical analysis
The statistical analysis was performed using the Sigma Stat 2.3
program. Descriptive statistics were applied to determine the
mean and standard deviation and to evaluate the differences be-
tween the groups analyzed. The variables were tested for normal
distribution and homogeneous variance. As they presented normal
distribution, variance analysis was used. The differences noted
were considered signiﬁcant when p < 0.05.3. Results and discussion
This study analyzed the use of alternative sources of energy
production by T. crassiceps cysticerci after the host treatment with
low dosages of antihelminthic drugs that impair the glucose up-
take and the traditional energy production pathways. This study
detected the adaptation of the parasite when facing a hostile envi-
ronment inside its host.
It was possible to detect in cysticerci removed from mice
treated with 5.75 and 11.5 mg/kg of albendazole and 3.83 to
7.67 mg/kg of praziquantel the production of organic acids that
indicate the oxidation of fatty acids such as acetoacetate, beta-
hydoxybutirate and propionate (Tables 1 and 2).
It was not possible to detect acetate in the analyzed samples.
We believe that this occurred similarly to what occurs in mammals
as the acetate was combined with acetyl-CoA originating acetoac-
etyl-CoA which is combined with acetyl-CoA forming beta-hydro-
xy-beta-methylglutaryl-CoA which is used to form acetoacetate
which may be excreted (Lehninger et al., 2006). In accordance to
the description made by Vinaud et al. (2009) in in vitro studies
which did not detect any difference between the production of ace-
tate from T. crassiceps cysticerci after exposure to the same drugs.
Other studies with cestodes such as Echinococcus granulosus and
Hymenolepis diminuta showed an increase in acetate production
when there is excess of intramitochondrial pyruvate as the
produced acetate is not converted into acetyl-CoA which is a sub-
strate to the tricarboxylic acid cycle (Melhorn et al., 1988; Vinaud
et al., 2009).
Table 1
Concentration (mean ± standard deviation) of products from T. crassiceps cysticerci from initial, larval and ﬁnal phases after host treatment with albendazole.
Control ABDZ 5.75 mg/kg ABDZ 11.5 mg/kg
Initial Larval Final Initial Larval Final Initial Larval Final
Urea (mg/dL) 2.40 ± 1.00 5.75 ± 3.5 2.00 ± 1.00 1.00 ± 1.00 3.00 ± 2.00* 1.20 ± 1.00 2.34 ± 1.00 3.44 ± 1.50 1.83 ± 1.00
Beta-hydroxybutirate (pMol/L) 2.37 ± 0.90 10.32 ± 6.28* 1.80 ± 0.82 3.07 ± 0.74 23.46 ± 3.26* 2.39 ± 0.43 1.38 ± 0.86 6.83 ± 3.26* 1.30 ± 0.56
Propionate (pMol/L) 1.79 ± 1.51 5.29 ± 1.21* 1.47 ± 0.99 2.44 ± 1.59 1.74 ± 1.31 1.88 ± 1.05 1.83 ± 1.14 1.58 ± 1.19 3.05 ± 1.71*
ABDZ – albendazole.
* p < 0.05.
Table 2
Concentration (mean ± standard deviation) of products from Taenia crassiceps cysticerci from initial, larval and ﬁnal phases after host treatment with praziquantel.
Control PZQ 3.83 mg/kg PZQ 7.67 mg/kg
Initial Larval Final Initial Larval Final Initial Larval Final
Urea(mg/dL) 2.40 ± 1.00 5.75 ± 3.50 2.00 ± 1.00 2.00 ± 1.00 3.81 ± 1.75* 1.40 ± 1.00 1.33 ± 1.00 8.44 ± 3.75 1.33 ± 1.00
Beta-hydroxybutirate(pMol/L) 2.37 ± 0.90 10.32 ± 6.28* 1.80 ± 0.82 1.55 ± 0.69 7.19 ± 2.50* 1.83 ± 0.83 2.54 ± 0.87 2.37 ± 0.90 10.32 ± 6.28*
Propionate (pMol/L) 1.79 ± 1.51 5.29 ± 1.21 1.47 ± 0.99 2.05 ± 1.36 1.84 ± 1.33 2.41 ± 1.39 1.79 ± 1.32 1.79 ± 1.51 5.29 ± 1.21
PZQ – praziquantel.
* p < 0.05.
Fig. 1. Production of succinate from propionate (Adapted from Lehninger et al.,
2006).
Fig. 2. Pathway of creatinine and putrescine production from arginine (Adapted
from Metzler, 1977).
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samples. This result is in accordance to the description by Vinaud
et al. (2009) in in vitro studies. We believe that the acetoacetate
was probably consumed by D-beta-hydroxybutirate dehydroge-
nase enzyme to produce beta-hydroxybutirate (Lehninger et al.,
2006) similarly to what is observed in mammals.
The beta-hydroxybutirate production was greater by all larval
stages of the treated groups because the mode of action of both
drugs impair glucose uptake (Tables 1 and 2) (Venkatesan, 1998;
Horton, 2000). Therefore there is the activation of alternative
pathways of energy production such as the beta-oxidation of fattyacids similarly to what is observed in mammals (Lehninger et al.,
2006) and to what is described by Vinaud et al. (2009) when study-
ing this same parasite and detected an in vitro increase of the
secretion/excretion of this product by the ﬁnal stage cysticerci
after exposure to the same drugs.
The propionate production was greater by the ﬁnal stage trea-
ted with 11.5 mg/kg of albendazole when compared to the control
group (Table 1). We believe that this occurred because the mode of
action of this drug is to block the glucose uptake (Venkatesan,
1998; Horton, 2000) and therefore leading the parasite to use as
an alternative energy source the oxidation of fatty acids which re-
sults in the increase of propionate. The higher concentrations of
this product will lead to its conversion into succinate which may
be consumed as substrate to the electrons transporting chain in-
side the mitochondrion as it is observed in mammals (Lehninger
et al., 2006) (Fig 1).
The urea production was greater in cysticerci from the hosts
treated with 5.75 mg/kg of albendazole (Table 1). The same was
observed from the group which was treated with 3.83 mg/kg of
praziquantel (Table 2). We believe that this occurred in those larval
stages because there is a greater use of the carbonic chain from
amino acids to the nucleic acids synthesis (Lehninger et al., 2006;
Fig. 3. Use of alternative energy sources by Taenia crassiceps cysticerci after host treatment with low dosages of antihelminthic drugs. The ﬁgure represents a single cell from
the parasite. Amino acids catabolism and fatty acids oxidation results in urea excretion. E-products from the metabolism which are excreted.
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site’s survival because it is a pathway to the excretion of toxic
substances as described in Fasciola gigantica (Mohamed et al.,
2005) and in T. crassiceps cysticerci (Vinaud et al., 2009).
The creatinine production was not detected in any of the
analyzed samples. We suggest that this occurred because one of
the creatinine production pathways is from arginine (Fig 2) as
the amidine terminal group from arginine is transferred to the for-
mation of ornithine and consequently forming the guanidinoacetic
acid which is transformed in creatinine and present as an interme-
diary product glycine. The creatine kinase enzyme using a phos-
phate group converts creatine into phosphocreatine which is an
ATP source especially during muscle contractions in which the cre-
atine kinase enzyme perform the hydrolysis of the ADP forming
ATP and creatinine. The non detection of creatinine may be ex-
plained due to the use of arginine to poliamines production such
as putrescine which has an important role in nucleic acids and pro-
tein synthesis besides the modulation of ion channels during the
muscle contraction (Figs. 2 and 3) (Metzler, 1977).
In summary as the anti-helminthic drugs impair the glucose
uptake there is an enhancement of the use of alternative energy
sources such as the fatty acids oxidation and the amino acids
breakdown. The increase of the latter pathway leads to greater
urea excretion as it acts as a detoxiﬁcation mechanism. Also the
ornithine cycle produces fumarate which may be excreted, as de-
scribed previously by our group (Fraga et al., 2012) or used in
the TCA cycle as it may pass through the mitochondrion mem-
brane. On the other hand the increase of the fatty acids oxidationleads to production of Acetyl-CoA which is used in the TCA cycle
enabling the aerobic production of energy through the oxidative
phosphorylation in the electron transport chain (Fig. 3).
In conclusion it was possible to detect the oxidation of fatty
acids and the use of alternative energy sources in T. crassiceps cys-
ticerci after the host treatment with low dosages of antihelminthic
drugs. The used dosages were not capable of total blockage of the
glucose uptake however it was enough to alter the parasite’s
metabolism and to induce the use of alternative energy sources
such as fatty acids oxidation and amino acids catabolism. Therefore
the cysticerci exposed to the drugs through host treatment pre-
sented metabolic adaptations different from the ones described
after in vitro treatments which indicate a great host-parasite
interaction.
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